CTBP2 anticorps (full length)

N° du produit ABIN7877731

Cet anticorps anti-CTBP2 Monoclonal Souris (Clone PCRP-CTBP2-1A9) (ABIN7877731) détecte spécifiquement CTBP2 dans IF et FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour CTBP2 anticorps (full length) (ABIN7877731)

Antigène: CTBP2 (C-terminal Binding Protein 2 (CTBP2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CTBP2 est non-conjugé

Application: Immunofluorescence (IF), Flow Cytometry (FACS)

Classe de qualité: Carrier-free

Clone: PCRP-CTBP2-1A9

Détail du produit anti-CTBP2 anticorps

Épitope: full length

Fonction: CTBP2 Antibody / C-terminal-binding protein 2 (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: Recombinant full-length human CTBP2 protein was used as the immunogen for the CTBP2 antibody.

Isotype: IgG2b

Information d'application

Indications d'application: Optimal dilution of the CTBP2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the CTBP2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur CTBP2

Antigène: CTBP2 (C-terminal Binding Protein 2 (CTBP2))

Autre désignation: CTBP2

Sujet: The gene CTBP2 (C-terminal binding protein 2) encodes a member of the CtBP-family. The gene is mapped to human chromosome 21q21.3. It is found to be expressed ubiquitously, with higher expression in the heart, skeletal muscle, and pancreas. The gene CTBP2 (C-terminal binding protein 2) encodes a protein that functions as a transcriptional co-repressor of several tumor suppressor genes resulting in enhanced cancer cell migration and invasion. Its expression is found to be upregulated in hepatocellular carcinoma (HCC). It may be a potential prognostic marker for post liver resection HCC. It is involved in several types of tumor initiation, progression and response to therapy. It is found to interact with the C-terminal region of adenovirus type 2/5 E1A protein, a region that negatively regulates tumorigenicity and the extent of oncogenic transformation.

UniProt: P56545